CoChat

That which does not kill me makes me stronger; combining ERK 1/2 pathway inhibitors and BH 3 mimetics to kill tumour cells and prevent acquired resistance

Sale, Matthew J, Cook, Simon J · 2013 · British Journal of Pharmacology
Cited by 20

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Oncogenic mutations in RAS or BRAF can drive the inappropriate activation of the ERK 1/2. In many cases, tumour cells adapt to become addicted to this deregulated ERK 1/2 signalling for their proliferation, providing a therapeutic window for tumour‐selective growth inhibition. As a result, inhibition of ERK 1/2 signalling by BRAF or MEK 1/2 inhibitors is an attractive therapeutic strategy. Indeed, the first BRAF inhibitor, vemurafenib, has now been approved for clinical use, while clinical evaluation of MEK 1/2 inhibitors is at an advanced stage. Despite this progress, it is apparent that tumour cells adapt quickly to these new targeted agents so that tumours with acquired resistance can emerge within 6–9 months of primary treatment. One of the major reasons for this is that tumour cells typically respond to BRAF or MEK 1/2 inhibitors by undergoing a G 1 cell cycle arrest rather than dying. Indeed, although inhibition of ERK 1/2 invariably increases the expression of pro‐apoptotic BCL 2 family proteins, tumour cells undergo minimal apoptosis. This cytostatic response may simply provide the cell with the opportunity to adapt and acquire resistance. Here we discuss recent studies that demonstrate that combination of BRAF or MEK 1/2 inhibitors with inhibitors of pro‐survival BCL 2 proteins is synthetic lethal for ERK 1/2‐addicted tumour cells. This combination effectively transforms the cytostatic response of BRAF and MEK 1/2 inhibitors into a striking apoptotic cell death response. This not only augments the primary efficacy of BRAF and MEK 1/2 inhibitors but delays the onset of acquired resistance to these agents, validating their combination in the clinic. Linked Articles: This article is part of a themed section on Emerging Therapeutic Aspects in Oncology. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2013.169.issue‐8

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.12220

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 124

  1. Andrews M, 2012, Colorectal cancer promoted in a melanoma patient receiving dabrafenib (GSK2118436) in combination with MEK1/2 inhibitor trametinib (GSK1120212), Pigment Cell Melanoma Res, 25, 842
  2. 10.1111/j.1365-2133.2012.11155.x · DOI · Paper page
  3. 10.1158/1078-0432.CCR-11-1344 · DOI · Paper page
  4. 10.1158/0008-5472.CAN-08-2819 · DOI · Paper page
  5. 10.1038/cdd.2008.148 · DOI · Paper page
  6. 10.1002/ijc.24604 · DOI · Paper page
  7. Basile KJ, 2012, Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B‐RAF melanoma cells, Am J Cancer Res, 2, 726
  8. 10.1007/s10637-010-9392-8 · DOI · Paper page
  9. 10.1038/nrc3297 · DOI
  10. 10.1038/nrd3847 · DOI · Paper page
  11. 10.1126/science.286.5443.1358 · DOI · Paper page
  12. 10.1038/onc.2010.616 · DOI
  13. 10.1093/emboj/18.19.5321 · DOI · Paper page
  14. 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0 · DOI · Paper page
  15. 10.1056/NEJMoa1208958 · DOI · Paper page
  16. 10.1038/nrd839 · DOI · Paper page
  17. 10.1080/10428190902748971 · DOI
  18. Chapman P, 2012, Development of colonic adenomas and gastric polyps in BRAF mutant melanoma patients treated with vemurafenib, Pigment Cell Melanoma Res, 25, 847
  19. 10.1056/NEJMoa1103782 · DOI · Paper page
  20. 10.1016/j.molcel.2010.01.025 · DOI · Paper page
  21. 10.1038/onc.2009.52 · DOI · Paper page
  22. 10.1056/NEJMra025195 · doi:10.1056/nejmra025195 · Paper page
  23. 10.1158/2159-8290.CD-11-0341 · DOI · Paper page
  24. 10.1371/journal.pmed.0040316 · DOI · Paper page
  25. 10.1016/S0092-8674(00)80405-5 · DOI · Paper page
  26. 10.1158/1535-7163.MCT-07-0231 · DOI · Paper page
  27. 10.1038/nature00766 · DOI · Paper page
  28. 10.1016/j.ccr.2006.08.027 · DOI · Paper page
  29. 10.1074/jbc.M101714200 · DOI · Paper page
  30. 10.1016/S0960-9822(00)00728-4 · DOI · Paper page
  31. 10.1038/nrc969 · DOI · Paper page
  32. 10.1073/pnas.0905833106 · DOI · Paper page
  33. 10.1128/MCB.02061-07 · DOI · Paper page
  34. 10.1038/sj.emboj.7601723 · DOI · Paper page
  35. 10.1038/sj.onc.1203076 · DOI · Paper page
  36. 10.1093/annonc/mdq258 · DOI · Paper page
  37. Fox W, 1999, Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946‐1986, with relevant subsequent publications, Int J Tuberc Lung Dis, 3, S231
  38. 10.1074/jbc.M306614200 · DOI · Paper page
  39. 10.1172/JCI28281 · DOI · Paper page
  40. 10.1038/382511a0 · DOI · Paper page
  41. 10.1073/pnas.081074898 · DOI · Paper page
  42. 10.1158/2159-8290.CD-12-0386 · DOI · Paper page
  43. 10.1016/j.cell.2012.02.015 · DOI · Paper page
  44. 10.1158/1535-7163.MCT-11-0989 · DOI · Paper page
  45. 10.1097/JTO.0b013e3181e8b3a3 · DOI · Paper page
  46. 10.1038/nature08833 · DOI · Paper page
  47. 10.1158/1535-7163.MCT-11-1010 · DOI · Paper page
  48. 10.1158/1078-0432.CCR-11-0563 · DOI · Paper page
  49. 10.1016/j.cell.2009.12.040 · DOI · Paper page
  50. 10.1073/pnas.050586197 · DOI · Paper page
  51. 10.1073/pnas.1008990107 · DOI · Paper page
  52. 10.1016/j.bbamcr.2003.08.009 · DOI · Paper page
  53. 10.1158/1078-0432.CCR-11-1491 · DOI · Paper page
  54. 10.1089/108729002760220798 · DOI · Paper page
  55. 10.1016/j.ccr.2006.10.006 · DOI · Paper page
  56. 10.1158/0008-5472.CAN-07-1919 · DOI · Paper page
  57. 10.1038/leu.2011.287 · DOI · Paper page
  58. 10.1200/jco.2010.28.15_suppl.3534 · DOI · Paper page
  59. 10.1073/pnas.0606176103 · DOI · Paper page
  60. 10.1111/pcmr.12092 · DOI · Paper page
  61. 10.1074/jbc.M301010200 · DOI · Paper page
  62. 10.1016/j.ccr.2012.10.009 · DOI · Paper page
  63. 10.1126/scisignal.2001752 · DOI · Paper page
  64. 10.1038/onc.2012.160 · DOI
  65. 10.1038/cdd.2012.21 · DOI
  66. 10.1158/1535-7163.TARG-11-A229 · DOI
  67. 10.1158/0008-5472.CAN-07-6787 · DOI · Paper page
  68. 10.1038/nature09626 · DOI · Paper page
  69. 10.1182/blood-2008-02-137943 · DOI · Paper page
  70. 10.1200/JCO.2009.22.5748 · DOI · Paper page
  71. 10.1038/nature03579 · DOI · Paper page
  72. 10.1007/s00280-010-1265-5 · DOI
  73. 10.1016/j.lungcan.2011.05.005 · DOI · Paper page
  74. 10.1002/cncr.27790 · DOI
  75. 10.1126/science.278.5338.687 · DOI · Paper page
  76. 10.1038/nature08902 · DOI · Paper page
  77. 10.1158/1535-7163.MCT-08-0973 · DOI
  78. 10.1158/0008-5472.CAN-12-1365 · DOI
  79. 10.1152/ajpcell.1999.277.4.C652 · DOI · Paper page
  80. 10.1200/JCO.2011.34.7898 · DOI · Paper page
  81. 10.1111/j.1432-0436.2006.00075.x · DOI
  82. 10.1158/1078-0432.CCR-11-3090 · DOI · Paper page
  83. 10.1074/jbc.274.43.31108 · DOI · Paper page
  84. 10.1101/gad.836800 · DOI · Paper page
  85. 10.1146/annurev.med.59.090506.202405 · DOI · Paper page
  86. 10.1158/0008-5472.CAN-09-4471 · DOI · Paper page
  87. 10.1038/cddis.2011.137 · DOI
  88. 10.1074/jbc.M109907200 · DOI · Paper page
  89. 10.1074/jbc.M800271200 · DOI · Paper page
  90. 10.1038/onc.2010.380 · DOI · Paper page
  91. 10.1038/ncomms1727 · DOI · Paper page
  92. 10.1016/S0960-9822(00)00310-9 · DOI · Paper page
  93. 10.1158/1535-7163.MCT-08-0431 · DOI · Paper page
  94. 10.1038/nature04304 · DOI · Paper page
  95. 10.1158/1541-7786.MCR-11-0394 · DOI
  96. 10.1056/NEJMoa1105358 · DOI · Paper page
  97. 10.1158/0008-5472.CAN-11-1875 · DOI · Paper page
  98. 10.1038/nrm2952 · DOI · Paper page
  99. 10.1158/1535‐7163.MCT‐12‐0949 · DOI · Paper page
  100. 10.1074/jbc.274.49.34859 · DOI · Paper page
  101. 10.1056/NEJMoa1014209 · DOI · Paper page
  102. 10.1016/j.semcancer.2012.02.013 · DOI · Paper page
  103. 10.1056/NEJMc0904160 · DOI · Paper page
  104. 10.1158/0008-5472.CAN-07-5836 · DOI · Paper page
  105. 10.1158/0008-5472.CAN-08-3934 · DOI · Paper page
  106. 10.1101/gad.294104 · DOI · Paper page
  107. 10.1128/MCB.24.23.10340-10351.2004 · DOI
  108. 10.1016/j.ccr.2010.11.023 · DOI · Paper page
  109. 10.1200/JCO.2010.33.2312 · DOI · Paper page
  110. 10.1038/onc.2011.497 · DOI · Paper page
  111. 10.1158/0008-5472.CAN-10-4351 · DOI · Paper page
  112. 10.1158/1078-0432.CCR-07-0665 · DOI · Paper page
  113. 10.1126/scitranslmed.3000758 · DOI · Paper page
  114. 10.1038/onc.2008.335 · DOI · Paper page
  115. 10.1128/MCB.16.10.5546 · DOI · Paper page
  116. 10.1093/carcin/bgs330 · DOI · Paper page
  117. 10.1677/erc.1.0978 · DOI · Paper page
  118. 10.1038/ncb1676 · DOI · Paper page
  119. 10.1182/blood-2009-07-233304 · DOI · Paper page
  120. 10.1158/1078-0432.CCR-06-1150 · DOI · Paper page
  121. 10.1084/jem.20060353 · DOI · Paper page
  122. 10.1016/S0092-8674(00)81382-3 · DOI · Paper page
  123. 10.1038/sj.cdd.4401937 · DOI · Paper page
  124. 10.1038/sj.leu.2405098 · DOI · Paper page

Cited by

See all 20

Metadata

Authors
Sale, M. J., & Cook, S. J.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2013-07-26
Volume
169
Issue
8
Pages
1708-1722
ISSN
  • 0007-1188
  • 1476-5381
Cited by
20
References
23
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.